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Abstract 
In this study, magnetic iron oxide nanoparticle induced hyperthermia is applied for treatment 
of head and neck cancer using a mouse xenograft model of human head and neck cancer 
(Tu212 cell line). A hyperthermia system for heating iron oxide nanoparticles was developed 
by using alternating magnetic fields. Both theoretical simulation and experimental studies 
were performed to verify the thermotherapy effect. Experimental results showed that the 
temperature of the tumor center has dramatically elevated from around the room temper-
ature to about 40
oC within the first 5-10 minutes. Pathological studies demonstrate epithelial 
tumor cell destruction associated with the hyperthermia treatment. 
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Introduction 
The  modern  diagnosis  and  treatment  of  head 
and neck cancers (HNC) has now become more tai-
lored to the individual patient and to specific cancer 
types than before. A single agent capable of diagnos-
ing  cancer,  treating  it  and  monitoring  response  to 
treatment simultaneously provides an ideal solution 
for the patients. In recent years, advances in tumor 
cells  labeled  with  superparamagnetic  iron  oxide 
(SPIO) have provided increased understanding of the 
tumor  biology  and  tissue  microenvironment,  while 
also  offering  great  promise  for  the  development  of 
novel longitudinal monitoring and treatment evalua-
tion methods of HNC patients [1-2].  
Various  strategies  are  used  routinely  in  treat-
ment of HNC, including surgery, radiation therapy, 
and chemotherapy [3-4]. In recent years, ablative or 
thermotherapy has been developed for treatment of 
HNC, offering patients an alternative and minimally 
invasive  treatment  option  [5].  As  a  palliative  treat-
ment, the thermal treatment improves quality of life 
with decreased pain and preserves patient’s function 
and appearance. In addition, there is a reduction in 
tumor bulk and analgesia requirements. Advantages 
include a reduction in procedural cost, avoidance of 
complex repetitive surgeries, and an ability to visual-
ize the treated area at the time of the procedure. Ab-
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lation therapy is an evolving and exciting treatment 
option  in  the  head  and  neck  [6].  Among  various 
methods  of  thermotherapy,  magnetic  fluid  thermo-
therapy has drawn considerable attention [7-9]. In the 
magnetic  fluid  thermotherapy,  magnetic  fluids  con-
taining  magnetic  nanoparticles  (e.g.  iron  oxide)  are 
delivered to the cancer and then heated by external 
alternating magnetic field, resulting hyperthermia or 
thermo-ablation of cancer tissue. Recently, a magnetic 
alternating  current  hyperthermia  (MACH)  device 
using external magnetic coils was reported for local-
ized hyperthermia on head and neck cancer and lung 
cancer [10]. At the same time, magnetic nanoparticles 
based  nanotherapy  has  been  investigated  for  other 
types of tumors, for example, tumors of the central 
nervous system [11-12]. Additionally, nanotechnology 
has  been  applied  extensively  in  drug  delivery  and 
therapy  (including  chemotherapy)  [13-16],  con-
trast-enhanced multifunctional imaging [17], tracking 
of stem cells [18], targeted molecular and biomolecu-
lar imaging [19-21], etc.  
In this study, magnetic iron oxide nanoparticle 
(~15  nm  in  diameter)  induced  hyperthermia  is  ap-
plied for treatment of head and neck cancer using a 
mouse  xenograft  model  of  human  head  and  neck 
squamous cell carcinoma (HNSCC) cell line (Tu212). 
A  hyperthermia  system  for  remote  heating  of  iron 
oxide nanoparticles was developed using alternating 
magnetic fields. Both theoretical simulation and ex-
perimental  studies  were  performed  to  verify  the 
thermotherapy effect. It is expected that this transla-
tional research will provide an alternative to the ex-
isting HNC treatment approaches. 
Methods and Materials:  
Simulations of magnetic hyperthermia 
In the presence of time-varying magnetic field, 
magnetic  nanoparticles  will  realign  their  magnetic 
moments  to  the  applied  field.  The  process  of  rea-
lignment is characterized by the relaxation time con-
stants of nanoparticles, namely, Brownian and Néel 
time  constants.  As  the  excitation  frequency  of  the 
magnetic  field  increases,  magnetic  moments  of  na-
noparticles lag the applied field at a given angle. The 
resulting  power  dissipation  process  associated  with 
this  misalignment  can  increase  bulk  temperature  of 
magnetic nanoparticles and their surroundings. This 
phenomenon can be used as a method of hyperther-
mia,  suitable  for  cancer  treatment  in  low-perfusion 
tissue [22-24].  
Prior to experiments, theoretical simulation was 
carried out to estimate the temperature increase in a 
small low-perfusion tumor with volume of 1 mL (Vt = 
1 mL). Ferrofluid of volume 0.5 mL (Vf = 0.5 mL) were 
injected into the tumor and then heated up by high 
frequency  alternating  magnetic  fields.  We  assumed 
the ferrofluid was localized as a spherical core at the 
center  of  the  tumor  by  occupying  porous  tissue, 
therefore the total volume of the tumor after ferrofluid 
injection maintains at 1 mL. This assumption was also 
adopted in previous models [17-18]. Furthermore, we 
assumed  the  ferrofluid  was  homogeneously  distrib-
uted inside the spherical core with a radius of 4.9 mm 
(Rf = 4.9 mm). Additional simulation details are pro-
vided in the appendix. 
Cell and mice preparation 
 Human HNSCC cell lines Tu212 [25] were cul-
tured  in  DMEM/F12  (1:1)  medium  with  10%  (v/v) 
FBS in a humidified cell culture chamber (NuAire Inc. 
Plymouth, MN) at 37˚C, 5% CO2. Cells were passaged 
when they reached approximately 80-90% confluency.  
 Five nude (NCr) mice (body weight, approx. 25 
g) at 6-8 weeks of age  were obtained from Taconic 
Farms,  Inc.,  (Germantown,  NY).  Mice  were  main-
tained according to an approved Institutional Animal 
Care  and  Use  Committee  (IACUC)  protocol  at  the 
University of Georgia and the U.S. Public Health Ser-
vice (PHS) Policy on Humane Care and Use of La-
boratory Animals, updated 1996. Mice were kept in 
pathogen-free  cages  in  a  light  and  tempera-
ture-controlled  isolated  room  and  provided  with 
standard  rodent  chow  and  sterile  water  ad  libitum 
during  the  experimental  periods.  Tu212  cells  were 
harvested aseptically and a suspension (2×107 cells in 
0.05 to 0.10 mL PBS) was injected subcutaneously into 
the flank of nude mice to establish tumor xenograft. 
Tumor  growth  and  body  weight  were  monitored 
every other day. Tumor volume was assessed using 
digital  calipers  as  described  previously  where  the 
volume  was  the  product  of  largest  dimension  and 
(smallest dimension)2 × 0.52 [26]. After approximately 
4  weeks  the  tumor  volume  reached  approximately 
1cm3. Three mice were selected to receive the hyper-
thermia treatment as the experimental group, and the 
remaining two mice were kept as the control group, as 
described below. Mice were observed every other day 
until after tumor implantation and for 24-48 hr after 
treatment and imaging for their general appearance as 
well  as  the  treatment-mediated  toxicities  such  as 
weight change, blood in stool, and decreased activity. 
Magnetic Resonance Imaging (MRI)  
MRI was performed to monitor the tumor before 
treatment. MR images were acquired using fast spin 
echo pulse sequences for the morphological studies of 
the tumors on a Varian 7 T 210mm bore MR scanner. Theranostics 2012, 2(1) 
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Mice  were  anesthetized  initially  using  3%  isofluane 
mixed  with  oxygen  in  an  induction  chamber  and 
maintained at 1.5% isofluane mixed with oxygen via a 
nose bane. The MRI parameters are: TE = 10 ms, TR = 
2000 ms, FOV =40 mm, slice thickness = 1 mm, matrix 
size = 256 × 256, 7 axial slices, gap = 1 mm.  
Hyperthermia using an alternating magnetic 
field 
A solenoid coil (4 cm in diameter and 10 cm in 
length) was wound on a plastic tube (3.8 cm ID and 
4.0  cm  OD)  using  a  gauge  16  copper  wire.  An  im-
pedance matching circuit, consisting of power resis-
tors  and  capacitors,  was  made  before  the  coil  was 
driven by a power amplifier (Hafler Model# P3000, 
AZ, USA). First, a signal generator produced a small 
sinusoidal signal of 130 kHz, which was then ampli-
fied to 9 A (peak to peak value) to generate an alter-
nating magnetic field (AMF) around 7 kA/m inside 
the tube to heat SPIO nanoparticles. An optical fiber 
temperature  probe  (FISO,  Quebec,  Canada)  was  in-
serted  to  the  tumor  center  during  the  treatment  to 
monitor temperature.  
After MRI, 0.5 mL ferrofluid of SPIO nanoparti-
cles (magnetite (Fe3O4) particles, with size of ~15nm in 
diameter and 5.8% volume fraction or an equivalent 
concentration of 0.30 g/mL, Ferrotec Co. EMG 705, 
NH, USA) was used as hyperthermia media. The fluid 
was delivered through intratumoral injection for the 
experimental group (6 mice). Figure 1 illustrates the 
hyperthermia experimental scheme, where the mouse 
is  placed  inside  the  solenoid  coil  (blue  color)  with 
tumor positioned at the coil center in order to expose 
the tumor to the strongest magnetic field generated by 
the coil. The control group (2 mice) went through the 
hyperthermia but without nanoparticles injected.  
 
Estimate of SAR in hyperthermia experiment 
The  SAR  (Specific  Absorption  Rate)  is  used  to 
describe  the  quantification  of  heat  generation  from 
magnetic  particles.  Experimentally,  it  can  be  meas-
ured by the following equation [1]: 
         
  
    
  
  
     …(1) 
Where C=1500J/(kg.K) is mass based specific heating 
capacity of mixture of ferrofluid and tissue fluids [27], 
∆T is the amount of temperature change over time ∆t, 
the ratio of (∆T/∆t)i is the initial gradient or slope of a 
heating curve (temperature vs. time), mf=1.19 g/mL is 
the  density  of  ferrofluid,  and  mp=  0.3  g/mL  is  the 
density of Fe3O4 in the fluid. 
 
 
Figure  1  Illustration  of  the  hyperthermia  experimental 
scheme, where the mouse is placed inside the solenoid coil 
(blue color) with tumor positioned at the coil center in 
order to expose the tumor to the strongest magnetic field 
generated by the coil. 
 
Preparation of tumor tissues 
At 24-48 hours post treatment mice were sacri-
ficed and tumor tissues were removed. Removed tu-
mor tissues were fixed in 10% formalin and routinely 
processed and embedded in paraffin. Sections were 
cut and stained with hematoxylin and eosin (HE) and 
Perl’s iron stain. For the Perl’s iron stain, 4-5 micron 
sections were microwaved in potassium ferrocyanide 
hydrochloric acid solution for 30 seconds, rinsed in 
deionized water, and counterstained with nuclear fast 
red  Kernechtrot  solution  for  3-5  min,  rinsed  in  tap 
water, dehydrated and mounted. Additional sections 
were  stained  by  caspase  3  (cleaved)  immunohisto-
chemistry to detect apoptosis. Briefly, 4-5 micron sec-
tions were deparaffinized, heated at 120 degrees for 8 
minutes in Tris/EDTA High pH 9.0 buffer, incubated 
with rabbit anti-Caspase 3 (cleaved) antibody (1:200 
dilution  for  60  min;Biocare,  Concord,  CA),  and 
blocked  with  power  block  (Biogenex,  San  Ramon, 
CA). Antibody was then detected with an streptavi-
din-biotin alkaline phosphatase method (biotinylated 
anti-rabbit;Vector Labs, Burlingame, CA and alkaline 
phosphatase labeled streptavidin; Biogenex, San Ra-
mon, CA) and Warp Red chromogen (Biocare, Con-
cord, CA). 
Results  
Simulation and experimental results of hy-
perthermia 
Figure 2 presents the simulation model and re-
sults. Simulation parameters are chosen to match the 
experimental conditions. Fig. 2(a) shows the location Theranostics 2012, 2(1) 
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of ferrofluids core (inner circle, Vf = 0.5 mL) within a 
spherical  tumor  (outer  circle,  Vt =  1  mL).  Magnetic 
field frequency is 130 kHz (f = 130 kHz), and field 
strength is 7000 A/m (peak to peak value H = 7000 
A/m). Fig. 2(b) depicts the temperature increase over 
time  at  the  center  of  the  tumor,  where  the  thermal 
probe is located in the subsequent experiments. Based 
on  our  experimental  conditions,  the  temperature  of 
the tumor is predicted to increase ~20 degrees with 10 
minutes application of magnetic fields, which match-
es  the  experimental  results  reasonably  well,  as  de-
tailed below. 
Figure 3 displays the in vivo experimental results. 
Fig. 3(a) shows MR image of one of tumors (circled 
and  labeled)  in  the  experiment  group  before  treat-
ment.  Fig.  3(b)  presents  the  temperature  curves  of 
experimental group tumors (4 out of the total of 6) 
during  the  hyperthermia  treatment.  Based  on  the 
graph, the temperature of the tumor center has dra-
matically elevated from around the room temperature 
to about 40oC within the first 5-10 minutes. Then, the 
amount of current flowing in the solenoid coil was 
controlled  to  maintain  the  regional  temperature  be-
tween  40oC  to  50oC.  The  entire  hyperthermia  treat-
ment took approximately 20 minutes.  
 
                    
Figure 2 presents the simulation model and results. Simulation parameters are chosen to match the experimental condi-
tions. (a) shows the location of ferrofluids core (inner circle, Vf = 0.5 mL) within a spherical tumor (outer circle, Vt = 1 mL). 
Magnetic field frequency is 130 kHz (f = 130 kHz), and field strength is 7000 A/m (peak to peak value H = 7000 A/m). (b) 
depicts the temperature increase over time at the center of the tumor, where the thermal probe is located in the subse-
quent experiments. 
 
      
Figure 3 In vivo experimental results: (a) shows the mouse MR image (tumor labeled) in the experiment group before 
treatment. (b) presents the temperature curves of experimental group tumors during the hyperthermia treatment. Based on 
the graph, the temperature of the tumor center has dramatically elevated from around the room temperature to about 40
oC 
within the first 5 minutes, then temperature maintains in between 40
oC to 50
oC. The entire hyperthermia treatment took 
approximately 20 minutes. Theranostics 2012, 2(1) 
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 Table 1 gives the SAR estimate (eq. 1) based on 
the experimental temperature curve of Fig. 3(b). The 
column 2-4 list the temperature measurement at 0.5 
min (T1), 2.5 min (T2), temperature gradient or slope, 
and  SAR  estimate.  As  a  comparison  to  the  in  vivo 
results, 3 pure ferrofluid samples were made of EMG 
705 (0.5 mL) sealed in a 1 mL plastic vial. They were 
heated  with  the  designed  coil  using  the  same  fre-
quency  and  magnetic  field  strength  as  those  of  the 
mouse  experiments.  The  column  5-7  list  the  corre-
sponding results.  
Histopathology 
Both treated and nontreated tumors were com-
posed of one or more circumscribed nodules that had 
a  peripheral  wall  of  neoplastic  stratified  squamous 
epithelium,  which  differentiated  centripetally,  and 
central necrosis. Treated tumors had variable degrees 
of ulceration and inflammation of the tumor wall as 
compared to the nontreated control tumors that had 
none (Figure 4). Remaining epithelium in the wall of 
treated  tumors  was  mostly  viable,  but  coagulative 
necrosis was present in one. Treated tumors also had 
more  severe  inflammation  around  the  tumor  and 
within  the  wall  and  centers  of  the  tumors  than  the 
nontreated controls. No stainable iron was observed 
in the nontreated controls. However, the treated tu-
mors had abundant iron  which  was free and intra-
cellular (cytoplasmic and nuclear) in the tumor cen-
ters, rarely in the cytoplasm and nuclei of the wall, 
and then only in necrotic cells, and around the tumors 
as extracellular lakes and cytoplasmic in macrophag-
es,  fibroblasts  and  adipocytes  (Figure  5).  Caspase  3 
staining  was  similar  between  the  treated  and  non-
treated tumors, with staining of multiple small groups 
of epithelial cells and inflammatory cells at the inter-
face between the wall epithelium and in the central 
area of necrosis (Figure 6).  
 
Table 1. Estimation of SAR based on the in vivo experiments and pure ferrofluid samples. The column 2-4 list the in vivo 
experiments, and column 5-7 list those of pure ferrofluid samples. Row 2-6 present the temperature measurements at 0.5 
min (T1), 2.5 min (T2), temperature gradient or slope, SAR estimate, and average SAR. 
  Mouse 1  Mouse 2   Mouse 3  Vial 1  Vial 2  Vial 3 
T1 (°C)  26.0  29.5  28.2  27.7  30.8  28.4 
T2 (°C)  40.5  39.0  36.5  57.8  60.8  58.2 
(∆T/∆t)avg  
 (°C /min) 
7.3  4.7  4.2  15.1  15.0  14.9 
SAR(W/kg)  723.9  466.1  416.5  1497.5  1487.6  1477.6 
Average SAR 
(W/kg) 
535.5  1487.6 
 
 
        
Figure 4 (a): Nontreated tumor without ulceration of the tumor wall. Note intact epithelium forming wall (W) and necrotic 
center (N) compared to (b): Treated tumor with severe ulceration of the wall with extensive loss of epithelium, indicative 
of cellular destruction, and infiltration with inflammatory cells (U). Note brown peritumoral iron (I) at the lower-left (in 
white color). HE stain. Bar= 1mm. Theranostics 2012, 2(1) 
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Figure 5 (a): Center of treated tumor demonstrating cytoplasmic and nuclear iron staining (seen as blue or green) in 
necrotic epithelium (E) and extracellular iron (arrow). Perl’s iron stain. Bar= 100 microns; (b): Extensive iron staining (seen 
as blue or green) around a tumor that is cytoplasmic in macrophages, fibroblasts, and adipose tissue (A). Tumor wall (W) 
does not have any iron staining. Perl’s iron stain. Bar= 200 microns. 
 
 
Figure 6 Caspase 3 immunohistochemical staining was similar between treated and nontreated tumors occurring at the 
interface (arrows) of the epithelium (E) of the wall and the necrotic center (N). Shown is a treated tumor. Avidin-biotin 
alkaline phosphatase technique. Warp red chromogen and hematoxylin counterstain. Bar=200 microns. 
 
Discussion and Conclusion 
In  this  study  we  demonstrated  that  magnetic 
heating of iron oxide nanoparticles can be achieved by 
applying an alternating magnetic field. This was ap-
plied to a mouse xenograft model of human HNSCC 
(Tu212 cell line).  
The  designed  solenoid  coil  generates  the 
strongest and most uniform magnetic field around the 
center of the coil. The thermal power density is pro-
portional to the square of magnetic field H (eq. (1) of 
the Appendix). It is anticipated that the optimal hy-
perthermia is generated when the tumor is positioned 
at the center of the coil. As seen in the Table 1, the SAR 
of in vivo experiments (535 W/kg) is about one third 
of  that  (1487  W/kg)  generated  by  pure  ferrofluid 
samples. The lower SAR of in vivo result is possibly 
due  to  heat  transfer  between  the  tumor  and  sur-
rounding tissues, and fast heat dissipation because of 
the blood flow supplied to the tumor. Similar studies 
reported SAR of 10-80 W/g depending on magnetite 
(Fe3O4)  particle  size  and  alternating  magnetic  field 
frequency. [28] 
To improve heating efficiency and making sure 
the heating is focused on tumor only, a second coil can 
be applied to generate a static field magnetic field by 
using a pair of Maxwell coils (shown in orange color 
as in the Fig.1). A counter-rotating direct current (dc) 
running  in  the  Maxwell  pair  of  coils  generates  a 
roughly linear magnetic field with zero-crossing (i.e., 
zero magnetic field) at the middle of the two coils. 
When the tumor to be treated is placed around the Theranostics 2012, 2(1) 
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middle of the Maxwell coil, the alternating magnetic 
field (generated by the solenoid coil in blue color as 
shown in Fig.1) functions as designed to heat the na-
noparticles populated in the tumor. However, mag-
netic particles diffused or carried away from the tu-
mor  by  blood  flow  are  not  heated.  This  is  because 
when the particles are positioned in the static mag-
netic field generated by the Maxwell coil, the static 
field  (with  equal  or  larger  amplitude)  is  superim-
posed  on  the  alternating  magnetic  field,  Neel  and 
Brownian relaxations of the particles are blocked and 
heating  will  be  diminished.  This  will  significantly 
reduce heating to the normal tissues surrounding the 
tumors. 
In this proof of concept study, magnetic nano-
particles were delivered through intratumoral injec-
tion  in  order  to  keep  the  concentration  desired  for 
hyperthermia  effect.  A  systemic  delivery  of  the  na-
noparticles  to  the  tumor  by  specific  antibodies  was 
reported by other studies. [9]  
As seen in the histopathology results, severe ul-
ceration of the wall of treated tumors which was not 
seen in the nontreated controls can be attributed to 
cell death caused by the hyperthermia. The presence 
of coagulative necrosis of the epithelium in the wall of 
one treated tumor and no difference in caspase stain-
ing between treated and nontreated tumors indicates 
that most hyperthermia-mediated cell death is due to 
oncotic necrosis and not apoptosis. Severe inflamma-
tion in the treated tumors can also be explained by the 
hyperthermia-associated necrosis.  
The  thermal  therapy  can  be  combined  with 
chemotherapy and radiation for a potentially better 
treatment effect for HNC patients. In addition to as 
hyperthermia media, the magnetic nanoparticles can 
also  function  as  drug  carriers  for  an  image-guided 
delivery. [15] 
In summary, we demonstrated in this study that 
hyperthermia  using  magnetic  heating  of  iron  oxide 
nanoparticles can be achieved by applying an alter-
nating  magnetic  field.  In  vivo  experiments  using 
mouse xenograft models showed that the temperature 
of tumor center was elevated quickly to cause hyper-
thermia-mediated cell death due to oncotic necrosis.  
Supplementary Material 
Appendix: Mathematical Treatment of the simulation 
of heating experiment. 
http://www.thno.org/v02p0113s1.pdf 
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